Inmune Bio Stock Investor Sentiment
| INMB Stock | USD 2.71 0.07 2.52% |
About 53% of INmune Bio's investor base is interested to short. The analysis of the overall investor sentiment regarding INmune Bio suggests that many traders are impartial. The current market sentiment, together with INmune Bio's historical and current headlines, can help investors time the market. In addition, many technical investors use INmune Bio stock news signals to limit their universe of possible portfolio assets.
Comfort Level 47
Impartial
Panic | Confidence |
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use INmune Bio's input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward INmune Bio.
News SentimentBearish | Hype SentimentBearish | Insider SentimentAcquiring |
INmune Historical Sentiment
Although INmune Bio's investment sentiment alone cannot always predict changes in its future share prices, when combined with other fundamental and technical analysis, a better chance to time the market can be gained. Certain informational and emotional events regarding INmune, such as negative comments on social media and news outlets, may cause fear in the market and push INmune Bio's investors to sell their holdings. The opposite can also be true when favorable news is released; it may translate into optimism and boost the price of INmune.
INmune Bio Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards INmune Bio can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
INmune Bio Historical Investor Sentiment
Investor biases related to INmune Bio's public news can be used to forecast risks associated with an investment in INmune. The trend in average sentiment can be used to explain how an investor holding INmune can time the market purely based on public headlines and social activities around INmune Bio. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
INmune Bio's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for INmune Bio and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average INmune Bio news discussions. The higher the estimate score, the more favorable the investor's outlook on INmune Bio.
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of INmune Bio's Stock prices. Below is the latest headlines and news related to INmune Bio Stock. The global stock market is bearish. About 68% of major world exchanges and indexes are down. See today's market update for more information.
There is far too much social signal, news, headlines, and media speculation about INmune Bio that are available to investors today. This information is accessible both publicly - through INmune Bio's media outlets and privately, via word of mouth or internal channels. However, regardless of the source, the sheer volume of INmune-related data is difficult to distill into actionable insights, especially for investors who are not well-versed in the rapidly evolving tools and techniques of investment management.
A primary focus of INmune Bio news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of INmune Bio relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to INmune Bio's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive INmune Bio alpha.
INmune Largest EPS Surprises
Earnings surprises can significantly impact INmune Bio's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2019-03-29 | 2018-12-31 | -0.19 | -0.21 | -0.02 | 10 | ||
2020-03-11 | 2019-12-31 | -0.25 | -0.22 | 0.03 | 12 | ||
2023-08-07 | 2023-06-30 | -0.4 | -0.36 | 0.04 | 10 | ||
2021-05-05 | 2021-03-31 | -0.27 | -0.32 | -0.05 | 18 | ||
2021-03-04 | 2020-12-31 | -0.31 | -0.26 | 0.05 | 16 | ||
2025-05-08 | 2025-03-31 | -0.49 | -0.43 | 0.06 | 12 |
There is far too much social signal, news, headlines, and media speculation about INmune Bio that are available to investors today. This information is accessible both publicly - through INmune Bio's media outlets and privately, via word of mouth or internal channels. However, regardless of the source, the sheer volume of INmune-related data is difficult to distill into actionable insights, especially for investors who are not well-versed in the rapidly evolving tools and techniques of investment management.
A primary focus of INmune Bio news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of INmune Bio relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to INmune Bio's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive INmune Bio alpha.
INmune Bio Performance against Dow Jones
Price Growth (%) |
| Timeline |
1 | Acquisition by Juda Scott of 32500 shares of INmune Bio at 5.05 subject to Rule 16b-3 | 06/09/2025 |
2 | INmune Bio Inc. to Announce Top Line Results from MINDFuL Phase 2 Trial in Early Alzheimers on ... | 06/26/2025 |
3 | INmune Bio Stock Soars Friday On Alzheimers Treatment Hopes | 06/27/2025 |
4 | INmune Bio Reports Key Findings from Phase 2 MINDFuL Trial of XPro in Early Alzheimers Disease | 06/30/2025 |
5 | INmune slides again as Scotiabank, RJ cut ratings after Alzheimers drug miss | 07/01/2025 |
6 | INMB Maxim Group Lowers Price Target While Maintaining Buy Rating INMB Stock News | 07/02/2025 |
7 | INmune Bio to Present Phase 2 MINDFuL Trial Findings of XPro at | 07/24/2025 |
Complementary Tools for INmune Stock analysis
When running INmune Bio's price analysis, check to measure INmune Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy INmune Bio is operating at the current time. Most of INmune Bio's value examination focuses on studying past and present price action to predict the probability of INmune Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move INmune Bio's price. Additionally, you may evaluate how the addition of INmune Bio to your portfolios can decrease your overall portfolio volatility.
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. |